Overall Survival (All-cause Mortality)
Conditions
Brief summary
This protocol is a retrospective study using the observational data of the the Prostate, Lung, Colorectal, and Ovarian (PLCO) screening trial with over 150,000 participants aged 55-74 years to conduct a target trial emulation to examine the association between self-reported exercise and all cause and cause-specific mortality in apparently healthy, middle-aged and older adults. The PLCO includes assessments of participants' exercise level at two timepoints: at randomization into the PLCO trial (Q0) and 5-7 years after randomization into the PLCO (Q1).
Interventions
BEHAVIORALControl
0 or less than 1 day per week, with each session, on average \< 15 minutes.
BEHAVIORALExercise
\>/= 2 days per week of moderate or vigorous intensity, with each session, on average, \>/=20 minutes in duration.
Sponsors
City of Hope Medical Center
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
55 Years to 74 Years
Healthy volunteers
No
Inclusion criteria
* Adults enrolled into the PLCO screening trial. * Among participants reporting low exercise at Q0 (i.e., 0 or less than 1 day/week, with each session \<15 minutes in duration), completion of an exercise survey at Q1 as part of PLCO standard trial procedures no later than 5 years after reporting non-exercising status \[i.e., no exercise) at Q0. * No evidence of any of the following absolute contraindications to exercise: uncontrolled hypertension, symptomatic valvular disease; hypertrophic cardiomyopathy; unstable angina pectoris; primary pulmonary hypertension; heart failure; severe arrhythmia; diagnosed dementia; any form of cancer other than non-melanoma, and severe infectious disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (all-cause mortality) | up to 19 years | All-cause mortality (death from any cause) occurring within the follow-up period in the PLCO screening trial. |
| Cause-specific mortality | up to 19 years | Cause-specific mortality (cancer mortality, mortality from other causes) occurring within the total follow-up period in the PLCO screening trial. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cancer incidence | up to 19 years | Cancer incidence occurring within the total follow-up period in the PLCO screening trial. |
Countries
United States
Contacts
CONTACTLee W Jones, PhD
CONTACTLennie Wong, PhD
Outcome results
None listed